CD4 and non-small cell lung carcinoma: Another report, by Zhang and colleagues, in 92 stage III-IV NSCLC patients treated with durvalumab or chemoimmunotherapy found that those with higher absolute counts and percentages of CD4+ naïve T cells (≥ 5.5 cells/μl, ≥ 1.8%), CD4+ memory stem cells (≥ 64.5 cells/﻿μl, ≥ 17%) or absolute counts of CD8+ memory stem cells (≥ 23.5 cells/﻿μl) prior to therapy had superior PFS [70].